Geron Corporation has published a document detailing a post hoc analysis of the correlation between inflammatory cytokine levels and overall survival in patients with myelofibrosis who were relapsed or refractory to Janus-associated kinase inhibitor treatment and received imetelstat in the IMbark trial. The document describes results related to the effect of imetelstat on proinflammatory cytokines and its impact on clinical outcomes. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.